| __timestamp | Teva Pharmaceutical Industries Limited | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 5078000000 | 4241601.57 |
| Thursday, January 1, 2015 | 4717000000 | 5392385.38 |
| Friday, January 1, 2016 | 5096000000 | 7370036.73 |
| Sunday, January 1, 2017 | 4986000000 | 14970357 |
| Monday, January 1, 2018 | 4214000000 | 31413266 |
| Tuesday, January 1, 2019 | 3806000000 | 72279461 |
| Wednesday, January 1, 2020 | 3671000000 | 183907682 |
| Friday, January 1, 2021 | 3528000000 | 307644000 |
| Saturday, January 1, 2022 | 3445000000 | 472132000 |
| Sunday, January 1, 2023 | 3498000000 | 709539000 |
| Monday, January 1, 2024 | 3702000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: argenx SE and Teva Pharmaceutical Industries Limited, from 2014 to 2023.
Teva, a well-established name, has seen a steady decline in its SG&A expenses, dropping approximately 31% over the decade. This reduction reflects a strategic shift towards cost efficiency amidst market challenges. In contrast, argenx SE, a rising star, has experienced a staggering increase in SG&A expenses, growing by over 16,600% during the same period. This surge underscores argenx's aggressive expansion and investment in growth.
These contrasting trends highlight the diverse strategies employed by pharmaceutical companies to navigate the competitive landscape, offering valuable insights into their operational priorities.
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Cost Management Insights: SG&A Expenses for argenx SE and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc
Comparing SG&A Expenses: argenx SE vs Veracyte, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for argenx SE and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Genmab A/S
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated